Abstracts tagged "Early Rheumatoid Arthritis"

Abstract Number: 956 • 2016 ACR/ARHP Annual Meeting
The Effect of Treatment Adjustments Aimed at DAS Remission on Physical Functioning in Undifferentiated and Rheumatoid Arthritis Patients in Low Disease Activity
SA Bergstra¹, OM Olivas Vergara¹, G Akdemir¹, GM Steup-Beekman², HK Ronday³, JB Harbers⁴, RBM Landewé^5,6 and CF Allaart¹, ¹Department of Rheumatology, LUMC, Leiden, Netherlands, Leiden, Netherlands, ²Department of Rheumatology, Bronovo Hospital, The Hague, Netherlands, The Hague, Netherlands, ³Department of Rheumatology, HAGA hospital, The Hague, Netherlands, The Hague, Netherlands, ⁴Department of Rheumatology, Franciscus Hospital, Roosendaal, Netherlands, Roosendaal, Netherlands, ⁵Amsterdam Medical Center, Amsterdam, Netherlands, ⁶Zuyderland Medical Center, Heerlen, Netherlands, Heerlen, Netherlands
Background/Purpose: Should we aim at remission if patients are in low disease activity (LDA)? We assessed if rheumatoid or undifferentiated arthritis (RA, UA) patients who…
Abstract Number: 2536 • 2016 ACR/ARHP Annual Meeting
The Performance of a Single Centre Interventional Clinic in Early Rheumatoid Arthritis
Rok Jese¹, Ales Ambrozic², Natasa Gaspersic², Alojzija Hocevar¹, Boris Lestan¹, Milena Pavic Nikolic¹, Martina Plešivčnik Novljan², Sonja Praprotnik³, Ziga Rotar¹, Alenka Šipek Dolničar¹, Dasa Suput Skvarca¹ and Matija Tomsic¹, ¹Department of Rheumatology, University Medical Centre Ljubljana, Ljubljana, Slovenia, ²Department of Rheumatology, University Medical Centre Ljubljana, 1000 Ljubljana, Slovenia, ³Department of Rheumatology, University Medical Centre Ljubljana, Slovenia, Ljubljana, Slovenia
Background/Purpose: In early rheumatoid arthritis (RA), first assessment by a rheumatologist and/or initiation of disease-modifying anti-rheumatic drugs (DMARD) within 12 weeks of symptom onset are…
Abstract Number: 556 • 2015 ACR/ARHP Annual Meeting
Induction-Maintenance in Early RA: A Meta-Analysis of Trials Using MTX Plus Adalimumab As Induction Therapy
Sharzad Emamikia¹, Elizabeth V. Arkema², Noémi Györi¹, Jacqueline Detert³, Katerina Chatzidionysiou¹, Maxime Dougados⁴, Gerd Burmester⁵ and Ronald F. van Vollenhoven¹, ¹Department of Medicine, Unit for Clinical Therapy Research, Inflammatory Diseases (ClinTRID), The Karolinska Institute, Stockholm, Sweden, ²Karolinska Institutet, Stockholm, Sweden, ³Department of Rheumatology and Clinical Immunology, Germany, Charité - Universitätsmedizin Berlin, Berlin, Germany, ⁴Paris-Descartes University, Paris, France, ⁵Department of Rheumatology and Clinical Immunology, Charité - Universitätsmedizin Berlin, Berlin, Germany
Background/Purpose: The goal of rheumatoid arthritis (RA) treatment is remission or, when not achievable, low-disease-activity (LDA). Initial combined therapy with MTX + anti-TNF achieves these…
Abstract Number: 1948 • 2015 ACR/ARHP Annual Meeting
Early Rheumatoid Arthritis Patients Have Higher Fractions of Circulating Th2 Cells, Th17 Cells and Regulatory T Cells, Similar Fractions of Follicular Helper T Cells, and Lower Fractions of Th17/Th1 Cells and Th1 Cells Compared to Healthy Controls
Jayesh Pandya, Magnus Hallström, Kerstin Andersson, Inger Nordström, Anna-Carin Lundell and Anna Rudin, Dept of Rheumatology and Inflammation Research, The Sahlgrenska Academy at University of Gothenburg, Gothenburg, Sweden
Background/Purpose: A comprehensive analysis of the circulating T cell subtype pattern, including T helper 1 (Th1) cells, Th2 cells, Th17 cells, Th1/Th17 cells, T follicular…
Abstract Number: 3256 • 2015 ACR/ARHP Annual Meeting
Epigenetic Chromosome Conformations Predict MTX Responsiveness in Early Rheumatoid Arthritis Patients
Claudio Carini¹, Aroul Ramadass², Philip Jordan², Ewan Hunter², Alexandre Akoulitchev², Iain. B. McInnes³, Carl. S. Goodyear³ and Scottish Early Rheumatoid Arthritis Inception Cohort Investigators, ¹35 Cambridgepark Drive, Pfizer, Cambridge, MA, ²Oxford Biodynamics, Oxford, United Kingdom, ³Institute of Infection, Immunity and Inflammation, College of Medicine, Veterinary Medicine and Life Sciences, University of Glasgow, Glasgow, United Kingdom
Background/Purpose: In early rheumatoid arthritis (RA), it is not possible to predict response to first line DMARDs (e.g. methotrexate (MTX)) and as such treatment decisions…
Abstract Number: 50 • 2015 ACR/ARHP Annual Meeting
Characteristics and Outcomes Associated with Early Corticosteroid Use in a Large Multicenter Canadian RA Cohort
Kathleen Andersen¹, Daming Lin², Susan J. Bartlett^3,4, Gilles Boire⁵, Boulos Haraoui⁶, Carol Hitchon⁷, Shahin Jamal⁸, Edward C. Keystone⁹, Janet E. Pope¹⁰, Diane Tin¹¹, J Carter Thorne¹², VP Bykerk^13,14 and CATCH Investigators, ¹Hospital for Special Surgery, New York, NY, ²Rheumatology, Mount Sinai Hospital, University of Toronto, Toronto, ON, Canada, ³Division of Rheumatology, Johns Hopkins School of Medicine, Baltimore, MD, ⁴Medicine , Divisions of Clinical Epidemiology, Rheumatology, Respirology, McGill University, Montreal, QC, Canada, ⁵Department of Medicine/Division of Rheumatology, Université de Sherbrooke, Sherbrooke, QC, Canada, ⁶Institut de Rhumatologie, Montreal, QC, Canada, ⁷Department of Rheumatology, University of Manitoba, Winnipeg, MB, Canada, ⁸Vancouver Coastal Health, Vancouver, BC, Canada, ⁹Mount Sinai Hospital, University of Toronto, Toronto, ON, Canada, ¹⁰University of Western Ontario, London, ON, Canada, ¹¹The Arthritis Program, Southlake Regional Health Centre, Newmarket, ON, Canada, ¹²University of Toronto, Toronto, ON, Canada, ¹³Rheumatology, Hospital for Special Surgery, New York, NY, ¹⁴Medicine, Mount Sinai Hospital/University of Toronto, Toronto, ON, Canada
Background/Purpose: Synthetic glucocorticoids (steroids) are commonly used in RA to rapidly inhibit pro-inflammatory cytokines. They are frequently used as "bridge therapy", quickly dampening down the…
Abstract Number: 557 • 2015 ACR/ARHP Annual Meeting
Early Intensification of Treatment Induces Superior Outcomes in Two Randomized Trials According to Predicted Vs. Observed Radiographic Progression in Rheumatoid Arthritis
Adrian Levitsky¹, Marius C. Wick², Timo Möttönen³, Marjatta Leirisalo-Repo⁴, Leena Laasonen⁵, Hannu Kautiainen^6,7, Markku Korpela⁸, Ronald F. van Vollenhoven¹ and Vappu Rantalaiho⁸, ¹Department of Medicine, Unit for Clinical Therapy Research, Inflammatory Diseases (ClinTRID), The Karolinska Institute, Stockholm, Sweden, ²Radiology, Karolinska University Hospital, Stockholm, Sweden, ³Internal Medicine, Division of Rheumatology, Turku University Central Hospital, Turku, Finland, ⁴Rheumatology, University of Helsinki and Helsinki University Hospital, Helsinki, Finland, ⁵Helsinki Medical Imaging Center, University of Helsinki and Helsinki University Hospital, Helsinki, Finland, ⁶Unit of Primary Health Care, University of Helsinki and Helsinki University Hospital, Helsinki, Finland, ⁷Unit of Primary Health Care, Kuopio University Hospital, Kuopio, Finland, ⁸Department of Internal Medicine, Center for Rheumatic Diseases, Tampere University Hospital, Tampere, Finland
Background/Purpose: Predicted vs. Observed Radiographic Progression in early Rheumatoid Arthritis (POPeRA) is a method that has previously confirmed the relative radiographic efficacy of synthetic disease-modifying…
Abstract Number: 2129 • 2015 ACR/ARHP Annual Meeting
Treatment-Naïve, Early Rheumatoid Arthritis Patients Demonstrate Abnormalities of Vascular and Myocardial Function on Cardiac MRI
Bara Erhayiem¹, Adam McDiarmid¹, Peter Swoboda¹, Ananth Kidambi¹, David Ripley¹, Tarique Musa¹, Laura Dobson¹, Pankaj Garg¹, Sarah Horton², Raluca Dumitru³, Jacqueline Andrews⁴, John Greenwood⁵, Paul Emery^4,6, Sven Plein¹ and Maya H. Buch^2,7, ¹Leeds Institute of Cardiovascular And Metabolic Medicine, University of Leeds, Leeds, United Kingdom, ²Leeds Institute of Rheumatic & Musculoskeletal Medicine, University of Leeds, Leeds, United Kingdom, ³University of Leeds, Leeds Institute of Molecular Medicine and LMBRU, Leeds, United Kingdom, ⁴NIHR-Leeds Musculoskeletal Biomedical Research Unit and Leeds Institute of Rheumatic and Musculoskeletal Medicine, University of Leeds, Leeds, United Kingdom, ⁵Leeds Institute of Cardiovascular And Metabolic Medicinee, University of Leeds, Leeds, United Kingdom, ⁶Leeds Institute of Rheumatic and Musculoskeletal Medicine, University of Leeds, Leeds, United Kingdom, ⁷NIHR - Leeds Musculoskeletal Biomedical Research Unit, Leeds, United Kingdom
Treatment-na•ve, early rheumatoid arthritis patients demonstrate abnormalities of vascular and myocardial function on cardiac MRIB Erhayiem, A McDiarmid, PP Swoboda, A Kidambi, DP Ripley, TA…
Abstract Number: 434 • 2015 ACR/ARHP Annual Meeting
Duration of Remission By Currently Available Criteria Can Predict Physical Functioning, but Not Radiological Progression in Early Rheumatoid Arthritis Patients
Nicole P.C. Konijn¹, Lilian H.D. van Tuyl¹, Maarten Boers^1,2, D den Uyl¹, M.M. ter Wee¹, P.J.S.M. Kerstens^3,4, Alexandre E. Voskuyl⁵, Michael T. Nurmohamed^1,3, Dirkjan van Schaardenburg^3,6 and Willem F. Lems^1,3, ¹Rheumatology, Amsterdam Rheumatology and immunology Center, VU University medical center, Amsterdam, Netherlands, ²Epidemiology & Biostatistics, VU University medical center, Amsterdam, Netherlands, ³Rheumatology, Amsterdam Rheumatology and immunology Center, Reade, Amsterdam, Netherlands, ⁴Rheumatology, Westfriesgasthuis, Hoorn, Netherlands, ⁵Rheumatology, Amsterdam Rheumatology and immunology Center, location VU University medical center, Amsterdam, Netherlands, ⁶Rheumatology, Amsterdam Rheumatology and immunology Center, Academic Medical Center, Amsterdam, Netherlands
Background/Purpose: Several sets of remission criteria have been developed. The ACR/EULAR criteria were validated against their potential to predict prognosis of rheumatoid arthritis (RA) [1].…
Abstract Number: 568 • 2015 ACR/ARHP Annual Meeting
Superiority of Initial Combination- over Step up Therapy in Treatment to the Target of Remission in Daily Clinical Practice in Early Rheumatoid Arthritis Patients: Results from the DREAM Registry
Laura M.M. Steunebrink¹, G.A. Versteeg¹, Harald E. Vonkeman², Peter M. ten Klooster³, Ina H. Kuper¹, Arie E. van der Bijl⁴, Piet L.C.M. van Riel⁵ and Mart A.F.J. van de Laar¹, ¹Rheumatology, Medisch Spectrum Twente - Arthritis Center Twente, Enschede, Netherlands, ²Ariensplein 1, Medisch Spectrum Twente - Arthritis Center Twente, Enschede, Netherlands, ³Pcgr, University of Twente, Enschede, Netherlands, ⁴Isala Klinieken, Zwolle, Netherlands, ⁵Rheumatology, Bernhoven, Uden, Netherlands
Background/Purpose: Treat-to-target (T2T) of remission strategies has been widely accepted as the standard of care for patients with Rheumatoid Arthritis (RA). In early RA, implementation…
Abstract Number: 2595 • 2015 ACR/ARHP Annual Meeting
Autoantibodies to Citrullinated Fibrinogen, Anti-CCP2 and Anti-MCV Antibodies in Early Rheumatoid Arthritis Patients with Rapid Radiographic Progression at 1-Year
Yannick Degboé¹, Arnaud Constantin², Delphine Nigon³, Gabriel Tobon⁴, Martin Cornillet⁵, Thierry Schaeverbeke⁶, Gilles Chiocchia⁷, Pascale Nicaise-Roland⁸, Leonor Nogueira⁹, Guy Serre^5,10,11, Alain G. Cantagrel¹² and Adeline Ruyssen Witrand^13,14, ¹Rheumatology, Rheumatology Center, Purpan University Hospital, Toulouse, France, ²Inserm U558, Rheumatology Center, Purpan University Hospital, Toulouse, France, ³CHU Purpan, Toulouse, France, ⁴Rheumatology Department, la Cavale Blanche Hospital, Brest, France, ⁵Service de Biologie Cellulaire, C.H.U. Purpan, Toulouse, France, ⁶CHU Bordeaux, Bordeaux, France, ⁷Immunology-Rheumatology, INSERM U1173, paris, France, ⁸Immunology Department, Bichat Claude-bernard, Universitary Hospital, APHP, Paris, France, ⁹Immunology, UMR CNRS 5165, INSERM 1056, Toulouse, France, ¹⁰Cell Biology, Purpan University Hospital, Toulouse, France, ¹¹Unité Différenciation Épidermique et Autoimmunité Rhumatoïde, Unité Mixte de Recherche, INSERM,Toulouse, France, Toulouse, France, ¹²Rheumatology, Centre Hospitalier Universitaire, Toulouse Purpan, Toulouse, France, ¹³Rheumatolgy, CHU Purpan - Hôpital Pierre-Paul Riquet, Toulouse, France, ¹⁴UMR 1027, Inserm, Toulouse, France
Background/Purpose: We compared the ability of anti-CCP2, anti-mutated citrullinated vimentin (anti-MCV) and anti-citrullinated fibrinogen (AhFibA) antibodies to predict 1-year rapid radiographic progression (RRP; total Sharp…
Abstract Number: 454 • 2015 ACR/ARHP Annual Meeting
No Sex Bias in the Escalation of Therapy in the Treatment of Early Inflammatory Arthritis
Stephanie Garner¹, Cheryl Barnabe², Gilles Boire³, Carol Hitchon⁴, Edward C. Keystone⁵, Boulos Haraoui⁶, J Carter Thorne⁷, Diane Tin⁸, Janet E. Pope⁹, VP Bykerk¹⁰ and CATCH Investigators, ¹University of Calgary, Calgary, AB, Canada, ²Cumming School of Medicine, University of Calgary, Calgary, AB, Canada, ³Department of Medicine/Division of Rheumatology, Université de Sherbrooke, Sherbrooke, QC, Canada, ⁴Department of Rheumatology, University of Manitoba, Winnipeg, MB, Canada, ⁵Mount Sinai Hospital, University of Toronto, Toronto, ON, Canada, ⁶Institut de Rhumatologie, Montreal, QC, Canada, ⁷University of Toronto, Toronto, ON, Canada, ⁸The Arthritis Program, Southlake Regional Health Centre, Newmarket, ON, Canada, ⁹University of Western Ontario, London, ON, Canada, ¹⁰Rheumatology, Mount Sinai Hospital, University of Toronto, Toronto, ON, Canada
Background/Purpose: Several studies have shown that females with early inflammatory arthritis have higher disease activity, worse functional impairment and worse patient-reported outcomes but do not…
Abstract Number: 571 • 2015 ACR/ARHP Annual Meeting
Malignancy Data in Tofacitinib-Treated Japanese Patients with Rheumatoid Arthritis
Yoshiya Tanaka¹, Tsutomu Takeuchi², Hisashi Yamanaka³, Naonobu Sugiyama M.D., Ph.D⁴, Takunari Yoshinaga⁴, Kanae Togo⁴, Jamie Geier⁵, Mary Boy⁵ and Carol Connell⁵, ¹The First Department of Internal Medicine, University of Occupational and Environmental Health, Kitakyushu, Japan, ²Keio University School of Medicine, Tokyo, Japan, ³Tokyo Women’s Medical University, Tokyo, Japan, ⁴Pfizer Japan Inc, Tokyo, Japan, ⁵Pfizer Inc, Groton, CT
Background/Purpose: Tofacitinib is an oral Janus kinase inhibitor for the treatment of rheumatoid arthritis (RA). In the global tofacitinib RA clinical program, rates and types…
Abstract Number: 2620 • 2015 ACR/ARHP Annual Meeting
Predictive Value of Anti-Carbamylated Protein Antibodies in Patients with Early Arthritis
Cristina Regueiro¹, Diana Peiteado², Laura Nuño³, Alejandro Villalba⁴, Dora Pascual-Salcedo⁵, Ana Martínez⁶, Alejandro Balsa⁴ and Antonio Gonzalez⁷, ¹Instituto Investigacion Sanitaria - Hospital Clinico Universitario de Santiago, Santiago de Compostela, Spain, ²Instituto de Investigación Hospital Universitario La Paz (IDIPAZ), Madrid, Spain, ³Servicio de Reumatologia, Hospital Universitario La Paz, Madrid, Spain, ⁴Rheumatology, La Paz University Hospital-Rheumatology Department, Madrid, Spain, ⁵Immunology Unit, La Paz University Hospital-Immunology, Madrid, Spain, ⁶Immunology Unit, La Paz University Hospital-IdiPaz, MADRID, Spain, ⁷Instituto Investigacion Sanitaria-Hospital Clinico Universitario de Santiago, Santiago de Compostela, Spain
Background/Purpose: Anti-carbamylated protein (anti-CarP) antibodies have been described as a new type of autoantibodies specific of patients with rheumatoid arthritis (RA). They seem useful as…
Abstract Number: 466 • 2015 ACR/ARHP Annual Meeting
Clinical Factors, Anti-Citrullinated Peptide Antibodies and MRI-Detected Subclinical Inflammation in Relation to Progression from Clinically Suspect Arthralgia to Arthritis
H.W. van Steenbergen¹, L. Mangnus², M. Reijnierse³, T. W. J. Huizinga¹ and A.H.M. van der Helm- van Mil², ¹Leiden University Medical Center, Leiden, Netherlands, ²Rheumatology, Leiden University Medical Center, Leiden, Netherlands, ³Radiology, Leiden University Medical Center, Leiden, Netherlands
Background/Purpose: Patients with Clinically Suspect Arthralgia (CSA) have, according to their rheumatologists, an increased risk on rheumatoid arthritis (RA), but their actual outcome is unexplored.…

« Previous Page
1
…
8
9
10
11
12
…
18
Next Page »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].